BIO-
Bio-Rad Laboratories Inc
NYSE: BIO-B · HEALTHCARE · MEDICAL DEVICES
$279.10
-6.80% today
Updated 2026-04-30
Market cap
$8.08B
P/E ratio
10.75
P/S ratio
3.13x
EPS (TTM)
$27.85
Dividend yield
—
52W range
$247 – $321
Volume
0.0M
WallStSmart proprietary scores
51
out of 100
Grade: C
Hold
Investment rating
2.7
Growth
F9.0
Quality
A+6.5
Profitability
B8.7
Valuation
A5/9
Piotroski F-Score
Moderate
3.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
—
—
Intrinsic (DCF)
$2,187.51
Margin of safety
+86.51%
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.22 — safe zone
+ Profit margin 29.40% — above average
+ Free cash flow $119.10M — positive
+ 86.51% below intrinsic value
+ Debt/equity 0.20x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.80B | $2.67B | $2.57B | $2.58B | $2.58B |
| Net income | $-3.63B | $-637.32M | $-1.84B | $759.90M | $720.00M |
| EPS | — | — | — | — | $27.85 |
| Free cash flow | $80.29M | $218.26M | $266.20M | $374.60M | $119.10M |
| Profit margin | -129.45% | -23.86% | -71.86% | 29.42% | 29.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-11-06 | BARRY, JAMES | Sale | 700 | $306.18 |
| 2025-10-24 | DIVINCENZO, JONATHAN P. | Sale | 1,869 | — |
| 2025-10-24 | DIVINCENZO, JONATHAN P. | Buy | 1,869 | — |
Peer comparison
Smart narrative
Bio-Rad Laboratories Inc trades at $279.10. representing a P/E of 10.75x trailing earnings. Our Smart Value Score of 51/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 3.22, it sits in the safe zone. TTM revenue stands at $2.58B. with profit margins at 29.40%. Our DCF model estimates intrinsic value at $2,187.51.
Frequently asked questions
What is Bio-Rad Laboratories Inc's stock price?
Bio-Rad Laboratories Inc (BIO-B) trades at $279.10.
Is Bio-Rad Laboratories Inc overvalued?
Smart Value Score 51/100 (Grade C, Hold). DCF value $2,187.51.
What is the price target of Bio-Rad Laboratories Inc (BIO-B)?
The analyst target price is $—, representing NaN% downside from the current price of $279.10.
What is the intrinsic value of Bio-Rad Laboratories Inc (BIO-B)?
Based on our DCF model, intrinsic value is $2,187.51, a +86.5% margin of safety versus $279.10.
What is Bio-Rad Laboratories Inc's revenue?
TTM revenue is $2.58B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
3.22 — safe zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.13x
ROE10.80%
Beta1.16
50D MA$276.09
200D MA$283.49
Shares out0.01B
Float0.02B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—